Akizawa, Tadao
Kurita, Noriaki
Mizobuchi, Masahide
Fukagawa, Masafumi
Onishi, Yoshihiro
Yamaguchi, Takuhiro
Ellis, Alan R.
Fukuma, Shingo
Alan Brookhart, M.
Hasegawa, Takeshi
Kurokawa, Kiyoshi
Fukuhara, Shunichi
Article History
Received: 8 January 2015
Accepted: 14 December 2015
First Online: 13 April 2016
Competing interests
: T.A. has acted as a consultant for Kyowa Hakko Kirin, has received grants (research support) from Kyowa Hakko Kirin and is a member of a speakers’ bureau of Kyowa Hakko Kirin. S. Fukuhara has acted as a scientific advisor for Kyowa Hakko Kirin and has received grants (research support) from Kyowa Hakko Kirin. M.F. has acted as a consultant for Kyowa Hakko Kirin, has received honoraria from Kyowa Hakko Kirin and has received grants (research support) from Kyowa Hakko Kirin. A.E.R. has received research funding from Amgen for other projects unrelated to the MBD-5D; He has also received unrelated research funding from the UNC Center for Pharmacoepidemiology, which receives support from the pharmaceutical industry and from Merck. M.A.B. receives investigator-initiated research funding from the National Institutes of Health (R01 AG042845, R21 HD080214, R01 AG023178) and through contracts with the Agency for Healthcare Research and Quality’s DEcIDE program and the Patient Centered Outcomes Research Institute. He has also received investigator-initiated research support from Amgen and has sat on advisory boards for Amgen, Merck and Pfizer (honoraria received by institution). He has received consulting fees from RxAnte, Inc. and World Health Information Science Consultants, LLC. The other authors report having nothing to disclose.